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The role of estrogen receptors (ER) and progesterone
receptors (PR) in promoting breast cancer has been
documented [1]. These hormone receptors are present
in a large proportion of breast cancer, from 50% to 80%
of cases [2,3]. The prognostic value of ER and PR status
in breast cancer in predicting a good response to hor-
mone treatment has been established [4]. In contrast,
the pathophysiologic mechanism of both androgen
levels in circulating blood and androgen receptor (AR)
expression in breast carcinoma are less well defined.
The role played by androgens in the pathogenesis of
breast cancer is not well understood, in particular, the
mechanism by which testosterone exerts its prolifera-
tive or antiproliferative effects on breast carcinoma cells
remains unclear [5]. Recent biochemical and immuno-
histochemical studies indicate that ARs are expressed
in a considerable proportion of breast carcinomas, rang-
ing from 35% to 90% of cases [6,7]. In addition, a con-
sistent coexpression of ARs, ERs and PRs has been
demonstrated in the same breast cancer [8].
Breast cancer is a heterogeneous disease in mor-
phology, invasive behavior, metastatic capacity, hor-
mone expression, oncogene, tumor-suppressor gene
expression, and clinical outcome. Mucinous carcinoma
is a specific histologic type of breast cancer that is
characterized by abundant extracellular mucin. The
reported frequency of mucinous carcinoma of the
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Hormone receptors play important roles in breast cancer. We investigated the expression of hormone
receptors in breast cancer to evaluate the importance of hormone receptors in the clinicopathology
of breast cancer. Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR)
expression characteristics were evaluated using immunohistochemistry stain, comparing patient
age, tumor size and axillary lymph node status for 23 pure mucinous and 105 non-mucinous
infiltrating ductal carcinomas in the human female breast. Mucinous carcinoma with axillary
lymph node metastasis occurred less frequently than non-mucinous carcinoma (11.8% vs. 55.2%;
p = 0.01). Compared with the non-mucinous type, mucinous carcinoma specimens showed less
AR expression (21.7% vs. 51.4%; p = 0.01) but more ER expression (78.3% vs. 52.4%; p = 0.02). In
addition, AR expression was also associated with ER and/or PR coexpression (37/74, 50%) in
infiltrating ductal carcinoma. But only three of 20 (15%) mucinous carcinoma specimens with AR
expression had associated ER and/or PR coexpression. Our findings revealed that mucinous car-
cinoma samples from the breast show distinct clinicopathologic and hormone receptor expression
features compared to non-mucinous carcinoma.
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breast is about 1–6% [9]. It is generally thought that
the tumor is more prevalent in older women and has
a better prognosis than the more common ductal type
of breast cancer [10].
To evaluate and compare the clinicopathologic and
steroid receptor-expression characteristics of mucinous
and non-mucinous invasive breast cancers, we per-
formed immunohistochemical staining using monoclo-
nal antibodies of AR, ER and PR. The results revealed
that mucinous carcinoma has distinct histopathologic
features and hormone receptor-expression character-
istics compared with non-mucinous carcinoma.
MATERIALS AND METHODS
A total of 128 breast cancers including 23 cases of
pure mucinous carcinoma and 105 cases of infiltrating
ductal carcinoma were retrieved from the files of the
Pathology Department at Tzu Chi Hospital in Hualien,
Taiwan. Clinicopathologic information on patient age
and tumor size were obtained from patient records.
Procedure
Individual tissue sections of 4–5 μm with 23 cases 
of mucinous carcinoma and 105 cases of infiltrating
ductal carcinoma were deparaffinized and routine
streptavidin-biotin-peroxidase antigen retrieval im-
munostaining [11] with 3-amino-9-ethylcarbazole was
performed on paraffin-embedded archival tissues by
using primary rabbit anti-AR (1:50), mouse anti-ER
(1:100) and mouse anti-PR (1:50).
Following treatment with chromogen-AEC, the
sites for immunoprecipitate formation were identi-
fied by light microscopy. Positive and negative con-
trol sections were included with each assay. Samples
were regarded as positive for AR, ER and PR when at
least 10% of the tumor cells were assessed as nucleus
immunoreactive [8].
Statistical analysis
Associations for mucinous and non-mucinous carci-
nomas for AR expression and other tumor character-
istics were calculated using χ2 or Fisher’s exact tests.
A two-tailed p value of less than 0.05 was declared as
statistically significant.
RESULTS
All breast cancer patients were female, with 23 cases
of mucinous carcinoma and 105 cases of infiltrating
Table 1. Clinicopathology and immunohistochemistry of 128 breast cancers
Mucinous carcinoma (n = 23) Infiltrating ductal carcinoma (n = 105) p
Age (yr) 0.92
≥ 50 11 (47.8%) 49 (46.7%)
< 50 12 (52.2%) 56 (53.3%)
Mean 54.7 54.0
Tumor size (cm) 0.23
≤ 5 23 (100%) 96 (91.4%)
> 5 0 6 (8.6%)
Axillary node status 0.01
Positive 2 (11.8%) 53 (55.2%)
Negative 15 (88.2%) 43 (44.8%)
Estrogen receptor 0.02
Positive 18 (78.3%) 55 (52.4%)
Negative 5 (21.7%) 50 (47.6%)
Progesterone receptor 0.24
Positive 17 (73.9%) 64 (60.9%)
Negative 6 (26.1%) 41 (39.1%)
Androgen receptor 0.01
Positive 5 (21.7%) 54 (51.4%)
Negative 18 (78.3%) 51 (48.6%)
ductal carcinoma. There were no significant differences
in age and tumor size between the two carcinoma
types. Mucinous carcinoma with axillary lymph node
metastasis occurred less frequently than non-mucinous
carcinoma (11.8% vs. 55.2%; p = 0.01). All relevant clin-
icopathologic data on tumor size and axillary node sta-
tus are listed in Table 1. Hormone receptor-expression
characteristics of the 23 mucinous carcinomas and 105
non-mucinous infiltrating ductal carcinomas are also
listed in Table 1.
Hormone receptor study revealed greater expres-
sion of ER (Figure 1) (78.3% vs. 52.4%; p = 0.02) and
less expression of AR (Figure 2) (21.7% vs. 51.4%;
p = 0.01) in the mucinous type, with no significant dif-
ference in the expression of PR (Figure 3) (73.9% vs.
60.9%; p = 0.24).
AR expression was also associated with ER and/
or PR coexpression (37/74, 50%) in infiltrating ductal
carcinoma. But only three of 20 (15%) mucinous car-
cinomas with AR expression had associated ER and/
or PR coexpression (Table 2).
DISCUSSION
Numerous studies have demonstrated the role of 
ER and PR as strong predictors of a good response to
Androgen receptor expression in mucinous breast cancer
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Figure 1. Immunohistochemical staining of ER reveals nuclear
staining in mucinous carcinoma (AEC, 400×).
Figure 2. Immunohistochemical staining of AR reveals nuclear
staining in mucinous carcinoma (AEC, 400×).
Figure 3. Immunohistochemical staining of PR reveals nuclear
staining in mucinous carcinoma (AEC, 400×).
Table 2. Androgen receptor (AR) expression and simultaneous estrogen receptor (ER) and progesterone receptor (PR)
immunoreactivity in breast carcinoma
Mucinous carcinoma Infiltrating ductal carcinoma 
(n = 23) (n = 105)
AR (+) AR (−) AR (+) AR (−)
ER (+) PR (+) 3 (20%) 12 (80%) 26 (58%) 19 (42%)
ER (+) PR (−) 0 (0%) 3 (100%) 4 (40%) 6 (60%)
ER (−) PR (+) 0 (0%) 2 (100%) 7 (37%) 12 (63%)
ER (−) PR (−) 2 (67%) 1 (33.3%) 17 (55%) 14 (45%)
hormone therapy and chemotherapy in the manage-
ment of patients with breast carcinoma [12]. However,
the clinical significance and functional role of androgen
levels and of AR expression in breast cancer has not
been well defined. There is evidence that androgens
can directly stimulate the growth of human breast
cancer cell lines [13].
AR is a member of the larger nuclear receptor family
that mediates the biological functions of androgens
[14]. Some biochemical and immunohistochemical
data have indicated the presence of AR in breast can-
cer tissue. In particular, recent studies show that AR is
expressed in a considerable proportion of breast cancer,
from 35% to 90% of cases. The results of our study are
consistent with those of previous studies [6,7].
These data suggest that ARs are involved in the
pathogenesis of at least a subset of breast carcino-
mas. Some studies have focused on the pattern of AR
expression in different histologic subtypes of breast
cancer, but the majority of data refer only to ductal
carcinomas [1]. A strong and consistent AR positivity
has been described in in situ and invasive apocrine
carcinomas as well as apocrine metaplasia, and the
intense expression of AR was often accompanied by a
lack of ER and PR immunoreactivity. AR positivity
was therefore proposed as a specific marker of apocrine
differentiation [15]. In one series of invasive breast
carcinomas, intense AR was frequently expressed in
lobular carcinoma [16]. Moreover, our study showed
a strong widespread AR positivity in the majority of
infiltrating ductal carcinoma (54/105, 51.4%) and rare
expression in mucinous carcinoma (5/23, 21.7%; p =
0.01). Only one previous study reported mucinous
carcinoma exhibiting a relatively high frequency of
positivity for AR (3/6, 50%) in women over 85 years
old [17]. The reason why there was a low incidence of
expression (21.7%) of AR in mucinous carcinoma in
our study and the mechanism of AR in this type of
breast cancer are still unknown. Further study of more
cases should be performed in the future to resolve
these issues.
There was also a significant difference in ER expres-
sion between the two types of breast carcinoma (52.4%
in infiltrating vs. 78.3% in mucinous; p = 0.02). Our
results are again consistent with those of previous stud-
ies, which demonstrated a high frequency of expres-
sion of ER protein in mucinous breast cancer [18,19].
AR expression was associated with ER and/or 
PR coexpression—50% (37/74) in infiltrating ductal
carcinoma. But in mucinous carcinoma, it was only
15% (3/20).
In addition to breast cancer, AR also plays an im-
portant role in the development and progression of
prostate cancer. Both AR and androgen-converting
enzymes were found to be upregulated in high-grade
or advanced prostate cancer [20]. Recently, diben-
zoylmethane has been applied for advanced prostate
cancer through suppression of the function of AR
[21]. In future, this drug may be a new choice for the
treatment of advanced breast cancer with high AR
expression.
In conclusion, mucinous carcinomas of the breast
demonstrate less axillary lymph node metastasis, more
frequent expression of ER, and have a low frequency
of AR and low incidence of AR with ER and/or PR
coexpression compared to infiltrating ductal carci-
noma. Our results revealed that mucinous carcinoma
samples from the breast showed distinct clinicopathol-
ogy and hormone receptor-expression features when
compared to non-mucinous carcinoma samples.
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